• Neurizon has secured registered trademark protection for NEURIZON® across all priority global markets
• Completion of the US registration represents an important milestone for the Company's commercialisation strategy
• The trademark portfolio complements Neurizon's broader intellectual property strategy, including patent protection for its lead asset, NUZ-001

Neurizon Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF), a clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, has announced that it has completed registered trademark protection for NEURIZON® across all priority global commercial markets, including the United States (US), the European Union (EU), the United Kingdom (UK), Australia and Japan. The registrations collectively provide Neurizon with exclusive rights to use and protect its brand across the Company's core jurisdictions, supporting consistent global brand deployment and enforcement. All registrations cover Class 42 services, including pharmaceutical research and development, clinical trial-related services, and research and development in neurological therapeutics. This scope aligns directly with Neurizon's current clinical programs and planned global activities as the Company advances its lead asset, NUZ-001, which is supported by Neurizon's expanding global patent portfolio. The completion of Neurizon's global trademark registrations complements the Company's broader intellectual property strategy, which includes granted and pending patent protection for NUZ-001 across key pharmaceutical markets, and reinforces its evolution toward a globally positioned clinical-stage biotechnology company. Completion of the US registration is particularly significant, as the US represents the Company's primary long-term value-creation and commercialisation market. The registration provides a strong foundation for future US operations, including engagement with clinical trial partners, strategic collaborators, licensees and other third-party service providers, as Neurizon progresses toward later-stage development.